Yang et al., Afr J Tradit Complement Altern Med. (2014) 11(4):101-119 http://dx.doi.org/10.4314/ajtcam.v11i4.17 DA-CHENG-QI DECOCTION, A TRADITIONAL CHINESE HERBAL FORMULA, FOR INTESTINAL OBSTRUCTION: SYSTEMATIC REVIEW AND META-ANALYSIS

Bo Yang^{1*}, Feng-Ying Xu^{2*}, Hai-Jing Sun^{2*}, Zui Zou², Xue-Yin Shi², Chang-Quan Ling^{3#}, Ling Tang^{3#}

¹Kidney institute of CPLA, Division of Nephrology, Changzheng hospital, Second Military Medical University, Shanghai, China. ² Department of Anesthesiology, Changzheng Hospital, Second Military Medical University, Shanghai, China. ³ Department of traditional Chinese medicine, Changhai Hospital Second Military Medical University, Shanghai, China. *Equal contribution to this work.

*E-mail: tanglingyuyz@126.com, lingchangquan@gmail.com

Abstract

Background: This study was aimed at determining the effects and safety of Da-Cheng-Qi decoction (DCQD) or DCQD combined with conservative therapy in patients with intestinal obstruction.

Materials and Methods: PubMed, EMBASE, Cochrane Controlled Trials Register, and several other databases were searched. Randomised controlled trials (RCTs) of DCQD or DCQD plus conservative therapy in patients with intestinal obstruction were eligible. Therapeutic effect was estimated by the improvement of clinical manifestations and diagnostic imaging; dichotomous/ordinal data assessment of overall response to therapy, adverse effects; or continuous variable were identified, including time to first bowel movement, time to first flatus, length of hospital stay.

Results: Sixty eligible RCTs including 6,095 patients were identified. Response rate: (1) DCQD versus conservative therapy (6 RCTs, 361 patients, RR of respond =1.13; 95% CI 0.97 to 1.31). (2) DCQD plus conservative therapy versus conservative therapy (48 RCTs, 4,916 patients, RR of respond =1.25 which favoured DCQD plus conservative therapy; 95% CI 1.20 to 1.30). Treatment effect remained similar when RCTs at high risk of bias were excluded. Time to first flatus postoperatively: (1) DCQD versus conservative therapy (2 RCTs, 240 patients, SMD=-3.65; 95% CI -8.17 to 0.87). (2) DCQD plus conservative therapy versus conservative therapy (11 RCTs, 1,040 patients, SMD=-2.09 which favoured DCQD plus conservative therapy).

Conclusion: DCQD combined with conservative therapy may increase the success rate of conservative therapy for intestinal obstruction significantly and can shorten the duration of postoperative ileus in patients undergoing abdominal surgery compared with conservative therapy alone.

Key words: Da-Cheng-Qi-Tang; Intestinal Obstruction; Ileus; Intestinal Pseudo-Obstruction; Meta-Analysis.

Introduction

Intestinal obstruction refers to any impairment, arrest, or reversal of the normal flow of intestinal contents toward the anal canal. It can be classified according to pathogenesis: ileus (a transient impairment of bowel motility caused by operation, inflammation, metabolism, neurogenic reasons and drugs) and mechanical intestinal obstruction (a kind of obstruction caused by any mechanical reasons, such as adhesion, neoplasm or herniation. And it accounts for approximately 15% of all emergency department visits for acute abdominal pain (Williams et al., 2005)). Postoperative ileus and mechanical intestinal obstruction caused by postoperative adhesions are the predominant types respectively.(Moran, 2007; Kumar et al., 2009) For ileus, conservative therapy containing bowel rest, intubation and decompression, intravenous fluid resuscitation, antibiotics and sometimes cathartics are the main strategies of treatment. As for mechanical intestinal obstruction, surgery is warranted in patients with obstruction when conservative therapy does not resolve within 48 hrs after it initiated (Fevang et al., 2002). Conservative therapy has been shown to be successful in more than 70% of the patients with mechanical intestinal obstruction include bowel ischemia and perforation, which may lead to severe outcomes or even death. (Markogiannakis et al., 2007) The diagnosis and treatment of intestinal obstruction remains a challenge.

Da-Cheng-Qi decoction (DCQD), Dai-joki-to in Japanese, a classic Chinese herbal formula (Satoh, 2013), is commonly used for the treatment of intestinal obstruction besides modern medicine in Chinese hospitals (Qi et al, 2004). The main components of DCQD are *Radix et Rhizoma*

http://dx.doi.org/10.4314/ajtcam.v11i4.17

Rhei, Cortex Magnoliae Officinalis, Fructus Aurantii Immaturus and *Natrii Sulfas*. Herbs in formula can sometimes be slightly adjusted (*jiajian* in Chinese pinyin) by doctor's judgments about the patients' clinical manifestations. DCQD can be administered via oral or rectal, and is to be stopped if patients egrets. Though pharmacological studies have shown different positive effects of the single plant extracts in DCQD,(Xu et al., 2010; Tang et al., 2008; Qi et al., 2007; Gong et al., 2011) as a formula, efficacy or side-effects of DCQD has not been systematically assessed till now. Therefore, the objective of the systematic review and meta-analysis is to determine the effects (benefits and harms) of DCQD in the treatment of intestinal obstruction, in mono-therapy or in combination with conservative therapy, as compared to conservative therapy alone.

Methods

Search strategy and study selection.

A search of the medical literature was conducted using PubMed (up to July 2011), EMBASE (1980 to July 2011), Cochrane Controlled Trials Register (issue 7, 2011), Sinomed (up to July 2011), China National Knowledge Infrastructure (CNKI) database (1994 to July 2011), Wanfang Data (1989 to July 2011) and the VIP Information (1990 to July 2011). Randomised Controlled Trials (RCTs) comparing the effects of DCOD or DCOD plus conservative therapy with conservative therapy in adult patients with intestinal obstruction (ileus or mechanical) were eligible for inclusion. Trials using other pharmaco-therapies were eligible, as long as these were administered to both the intervention and control groups. Diagnosis of intestinal obstruction could be based on case history, clinical manifestations and diagnostic imaging (X-ray or computed tomography scan). The primary outcome of this meta-analysis was estimated by the improvement of clinical manifestations (relief of abdominal pain, passage of flatus/stool, bowel movement) and diagnostic imaging (X-ray or computed tomography scan). We attempted to contact the original investigators in order to obtain further information if necessary. Studies on intestinal obstruction were identified with the terms intestinal obstruction; intestinal pseudo-obstruction and ileus, (both as medical subject heading (MeSH) and free text terms), small bowel obstruction, SBO and large bowel obstruction (as free text terms). These were combined using the set operator AND, with studies identified using the terms: Da-Cheng-Qi-Tang, DCQT herbal medicine and Drugs, Chinese Herbal (MeSH terms), Da-Cheng-Qi decoction (free text terms). We also searched the reference lists of the original reports, reviews, letters to the editor, case reports and meta-analyses of studies involving Chinese herbal medicine (retrieved through the electronic searches) to identify studies which had not yet been included in the computerised databases, all potentially relevant papers were obtained and evaluated in detail. There were no language restrictions. Articles were independently assessed by two reviewers (YB and XFY) using predesigned eligibility criteria: 1) randomised controlled trials; 2) diagnosis of intestinal obstruction based on case history, clinical manifestations and diagnostic imaging (X-ray or computed tomography scan); 3) interventions: DCQD or DCQD plus conservative therapy compared with conservative therapy (DCQD jiajian was allowed); 4) decotion administered via oral and/or rectal; 5) therapeutic effect was estimated by the improvement of clinical manifestations (relief of abdominal pain, passage of flatus/stool, bowel movement) and/or diagnostic imaging (X-ray or computed tomography scan); 6) dichotomous/ordinal data assessment of overall response to therapy, adverse effects; or continuous variable were identified, including time to first flatus, time to first bowel movement, length of hospital stay. Any disagreement between reviewers was resolved by consensus between the two reviewers (YB and XFY), adjudicated with the support of a third reviewer (SHJ).

Outcome assessment

The primary outcome assessed was the obstruction cured or improvement at the end of treatment. Failure to response to therapy was defined as no improvement in clinical manifestations (ileus) or as needing surgical treatment (mechanical). If ordinal data were given to define obstruction improvement, they were transformed into dichotomous data (e.g. if the scale was 1, no improvement (ileus) or needs surgical treatment (mechanical); 2, a little improvement; 3, a moderate amount of improvement; 4, great improvement; the latter 3 descriptors were defined as positive outcomes). Secondary outcomes considered was continuous data defined as time to first flatus.

Data extraction

All data were extracted independently by two reviewers (Y.B. and SHJ) onto a pre-designed form (Microsoft Office Excel 2007; Microsoft Corp, Redmond, Washington, USA). All data extraction was then checked by a third reviewer (ZZ). The following data were extracted for each trial: number of centres; geographical location of the study; study population; sample size; proportion of female patients; criteria used to define

http://dx.doi.org/10.4314/ajtcam.v11i4.17

intestinal obstruction; aetiology (including detailed abdominal operation histories); the route of administration; duration of treatment; concomitant medications allowed; total number of adverse events reported; primary outcome measure used to define clinical manifestations improvement or cure following treatment; duration of follow-up; method used to generate the randomization schedule and conceal allocation. Data were extracted as intention-to-treat analyses, where all drop-outs were assumed to be treatment failures, wherever trial reporting allowed this.

Assessment of risk of bias

Assessment of risk of bias was performed independently by two reviewers (YB and SHJ), with disagreements resolved by discussion. Risk of bias was assessed according to the elaborated CONSORT checklist for herbal interventions (Gagnier et al., 2006, 2006) by recording characteristics of the herbal product, qualitative testing, dosage regimen and quantitative description, method used to generate the randomization schedule and conceal allocation, whether blinding was implemented, what proportion of patients completed follow-up, and whether an intention-to-treat analysis was extractable etc.. 2-properly with detailed description, 1-mentioned but not detailed reported, 0-not mentioned or inappropriate. A trial with a quality score ≤ 18 was considered as a trial at high risk of bias, and a trial with a quality score ≥ 36 was considered as a trial at low risk of bias, the left were at moderate risk of bias.

Data synthesis and statistical analysis

Data were pooled using a random effects model to produce wider confidence intervals and more conservative estimates.(DerSimonian et al., 1986) The impacts of DCQD on dichotomous outcomes were expressed as a relative risk (RR) of response to therapy with intervention compared with control with 95% confident intervals (CIs). The number needed to treat (NNT) with 95% CIs were calculated from the reciprocal of the risk difference of the meta-analysis. Time to first flatus was examined using a standardised mean difference (SMD) with a 95% CI.

Heterogeneity between studies was assessed using the I^2 statistic with a cut-off of > 50% to define a significant degree of heterogeneity. We conducted a pre-specified sensitivity analyses according to the type of intestinal obstruction, risk of bias of identified trials, detailed operation histories, the route of administration and the definition of response to therapy. These were exploratory analyses only, and may explain some of the observed variability, the results, however, should be interpreted with caution.

Review Manager Version 5.0 (The Nordic Cochrane Centre, The Cochrane Collaboration, 2008) and Stata/SE version 10.0 (StataCorp, College Station, Texas, USA), were used to generate forest plots for outcomes with 95% CIs, as well as funnel plots. The latter were assessed for evidence of asymmetry, and possible publication bias or other small study effects were evaluated using the Begg's test. (Begg et al., 1994)

Results

The search strategy initially yielded 752 citations, 109 of which appeared to be relevant to the systematic review and were retrieved for further assessment (Figure 1). Of these, 49 were excluded for various reasons, leaving a total of 60 eligible articles. Seven RCTs compared the effect of DCQD with conservative therapy, 54 compared the effect of DCQD plus conservative therapy with conservative therapy alone. Characteristics of the included trials were shown in supplementary Tables.

DCQD versus conservative therapy

The seven RCTs comparing DCQD with conservative therapy involved a total of 521 patients. Five trials were at moderate and two trials were at high risk of bias according to the modified elaborated CONSORT statement for herbal interventions. The pathogenesis in six RCTs was ileus while it was incomplete mechanical intestinal obstruction in one trial. Dichotomous data could be extracted from six RCTs. There were 24 (13.2%) of 182 patients assigned to DCQD who failed to respond to therapy, compared with 38 (21.2%) of 179 allocated to conservative therapy (RR of respond=1.13; 95% CI 0.97 to 1.31) (Fig 2). There was borderline heterogeneity between studies (I^2 =58%), with no statistically significant funnel plot asymmetry (Begg's test, p=1.00) suggesting no evidence of publication bias or other small study effects

Yang et al., Afr J Tradit Complement Altern Med. (2014) 11(4):101-119 http://dx.doi.org/10.4314/ajtcam.v11i4.17




Figure 1: Flow diagram of RCTs included

Table 1: Sensitivity analyses of efficacy of DCQD in intestinal obstruction

	Number of studies	Number of subjects	RR	95% CI	I^2 value	NNT	95% CI
All studies#	6	361	1.13	0.97 to 1.31	58%	N/A	N/A
Risk of bias of trial	S						
Moderate	5	301	1.14	0.95 to 1.39	66%	N/A	N/A
High	1	60	1.08	0.88 to 1.32	N/A	N/A	N/A
Route of administr	ation						
Via oral	4	231	1.08	0.84 to 1.39	67%	N/A	N/A
Via rectal	2	130	1.22	0.93 to 1.59	70%	N/A	N/A
Definition of respon	nse to therapy						
Clinical alone	4	301	1.07	0.91 to 1.25	65%	N/A	N/A
Clinical + Imaging	2	60	1.45	1.11 to 1.91	0%	3.2	2 to 7.7
Aetiology							
Postoperative	3	190	1.15	1.01 to 1.31	35%	7.7	4.2 to 50
Non-postoperative	3	171	1.11	0.72 to 1.73	78%	N/A	N/A

N/A, not applicable; # refers to the studies dichotomous data can be extracted from.

Response to therapy in patients with ileus

The five trials studying ileus reported dichotomous data of 301 patients. Overall, ileus was caused by operation in 190 patients. 21 (13.8%) of 152 patients assigned to DCQD failed to respond to therapy compared with 33 (22.1%) of 149 patients allocated to conservative therapy (RR of respond =1.14; 95% CI 0.95 to 1.39). There was significant heterogeneity between studies (I^2 =66%) with no evidence of funnel plot asymmetry (Begg's test, p=0.73). Two RCTs reported continuous data of the time to first flatus post-operatively. There was no statistical difference when results of individual RCTs were combined (SMD=-3.65; 95% CI -8.17 to 0.87) (Figure 3), and there was significant heterogeneity among these two studies (I^2 =99%).

Response to therapy in patients with mechanical intestinal obstruction

Only one trial containing 60 patients studied incomplete mechanical intestinal obstruction, 3 (10.0%) of 30 patients assigned to DCQD failed to respond to therapy compared with 5 (16.7%) of 30 patients allocated to conservative therapy (RR of respond =1.08; 95% CI 0.88 to 1.32) (Figure 2).

http://dx.doi.org/10.4314/ajtcam.v11i4.17

Sensitivity analysis

Given the borderline heterogeneity observed when results of individual RCTs were combined, we conducted pre-specified sensitivity analyses (Table 1). The RR of respond was relatively stable in these analyses. Heterogeneity between trials was lower and 95% CI doesn't include the number "1" when only the two studies that used clinical manifestations and imaging improvement to define response to therapy were included in the analysis. Treatment effect remained similar when only the five trials at low risk of bias were considered.

DCQD plus conservative therapy versus conservative therapy

The 54 RCTs comparing DCQD plus conservative therapy with conservative therapy contained a total of 5,574 patients with intestinal obstruction. 27 trials were at moderate and 27 trials were at high risk of bias. Twenty-one RCTs studied ileus while 33 studied mechanical intestinal obstruction. Dichotomous data could be extracted from 48 RCTs. There were 221 (8.4%) of 2,641 patients assigned to DCQD plus conservative therapy who failed to respond to therapy, compared with 648 (28.5%) of 2,275 allocated to conservative therapy alone (RR of respond=1.25; 95% CI 1.20 to 1.30 which favoured DCQD plus conservative therapy), with borderline heterogeneity between studies (I^2 =55%) (Fig 4) and an NNT of 5.3 (95% CI 4.8 to 6.3). There was no statistically significant funnel plot asymmetry (Begg's test, p=0.31) suggesting no evidence of publication bias or other small study effects.

Response to therapy in patients with ileus

In the 21 trials studying ileus, 15 reported dichotomous data in 1,168 patients. Overall, ileus of 879 patients was caused by operation. Fifty-one (8.4%) of 606 patients assigned to DCQD plus conservative therapy failed to respond to therapy compared with 150 (26.7%) of 562 patients allocated to conservative therapy (RR of respond =1.23; 95% CI 1.13 to 1.34 which favoured DCQD plus conservative therapy) (Fig 4), with significant heterogeneity between studies (I^2 =67%) and an NNT of 5.9 (95% CI 4.3 to 9.1). There was no evidence of funnel plot asymmetry (Begg's test, p=0.19).

Eleven RCTs reported continuous data of time to first flatus post-operatively. There was statistical difference when results of individual RCTs were combined (SMD=-2.09; 95% CI -3.04 to -1.15 which favoured DCQD plus conservative therapy) (Fig 3), and there was significant heterogeneity among studies (I^2 =97%).

	Number of studies	Number of subjects	RR	95% CI	I ² value	NNT	95% CI
All studies#	48	4,916	1.25	1.20 to 1.30	55%	5.3	4.8 to 6.3
Risk of bias of trials	5						
Moderate	23	1,996	1.24	1.16 to 1.33	69%	5.6	4.5 to 7.7
High	25	2,920	1.26	1.21 to 1.31	18%	5	4.3 to 5.9
Route of administra	ition						
Via oral	22	2,231	1.22	1.16 to 1.28	33%	5.9	5 to 7.7
Via rectal	12	1,072	1.32	1.24 to 1.39	0%	4.2	3.6 to 5.3
Oral and rectal	14	1,613	1.24	1.13 to 1.36	77%	5.6	4.2 to 9.1
Definition of respon	se to therapy						
Clinical alone	11	1,136	1.30	1.19 to 1.41	48%	4.8	3.7 to 6.3
Clinical + Imaging	37	3,780	1.24	1.18 to 1.29	55%	5.6	4.8 to 6.7
Aetiology							
Postoperative	35	3,724	1.22	1.17 to 1.27	53%	5.9	5 to 7.1
Non-postoperative	13	1,192	1.34	1.24 to 1.45	31%	4.2	3.6 to 5

Table 2: Sensitivity analyses of efficacy of DCQD plus conservative therapy in intestinal obstruction

refers to the studies dichotomous data can be extracted from

http://dx.doi.org/10.4314/ajtcam.v11i4.17

Supplementary Table 1: Characteristics of the included RCTs (part A)

	DOI	definition of intestinal	aetiolo		female	number of	averag	route of DCQD	duration of	duration of
trials		obstruction	gy	clinical background	patients	participants	e age	administration	treatment	follow-up
Ao XR	CNKI:SUN:JXZY.0.200	diagnostic imaging +	mecha	ab dominal average	4.4	06	44.4	(nasogastric	5 d	N/A
2007	7-07-039	clinical manifestations	nical	abdominal surgery	44	96	44.4	tube/oral) and rectal	5d	IN/A
Cao SB	CNKI:SUN:SXZY.0.20	diagnostic imaging +	ileus	N/A	26	69	71.1	rectal	7d	N/A
2008	08-09-031	clinical manifestations	neus	N/A	20	09	/1.1	lectal	74	IN/A
Chen CQ	cnki:ISSN:1009-9727.0.	clinical manifestations	ileus	stroke	71	180	58.5	nasogastric tube/oral	14d	N/A
2002	2002-03-017	alone	neus	SHOKE	/1	100	56.5	hasogastrie tube/orai	140	IV/A
Chen H	CNKI:SUN:CZXX.0.20	diagnostic imaging +	mecha	N/A	24	65	42.24	nasogastric tube/oral	78h	N/A
2009	09-04-045	clinical manifestations	nical	1.07.8	24	05	72.27	hasogastrie tube/orai	701	11/11
Chen ZJ	cnki:ISSN:1005-7331.0.	clinical manifestations	mecha	abdominal surgery	15	50	50.8	rectal	5d	N/A
2004	2004-02-027	alone	nical	abdominar surgery	15	50	50.8	rectar	54	
Dong ZC	CNKI:SUN:SXZY.0.20	diagnostic imaging +	mecha	abdominal surgery	27	68	56.9	(nasogastric	10d	N/A
2008	08-05-026	clinical manifestations	nical	abdominar surgery	21	00	00 50.7	tube/oral) and rectal	100	IV/A
Dou WH	CNKI:SUN:SHIX.0.200	diagnostic imaging +	mecha	abdominal surgery	34	80	41.8	nasogastric tube/oral	10d	N/A
2009	9-07-019	clinical manifestations	nical	abdominar surgery	54	80	41.0	husogustile tube, orur	100	IV/A
Fan Y	CNKI:ISSN:1003-5699.	clinical manifestations	mecha	abdominal surgery	N/A	60	N/A	nasogastric tube/oral	48h	N/A
2007	0.2007-03-019	alone	nical	abdommar surgery	14/21	00	IN/A			IN/A
Fang HL	CNKI:SUN:GAYX.0.20	diagnostic imaging +	mecha	abdominal surgery	267	538	N/A	(nasogastric	N/A	N/A
2008	08-04-076	clinical manifestations	nical	abdominar surgery	207	556	IN/A	tube/oral) and rectal	\mathbf{N}/\mathbf{A}	IV/A
Fu HB	CNKI:SUN:BHON.0.20	diagnostic imaging +	ileus	stroke	27	62	63.5	nasogastric tube/oral	3d	N/A
2008	08-03-026	clinical manifestations	neus	SHOKE	21	02	05.5	hasogastric tube/orar	50	IN/A
Gao JC	cnki:ISSN:1000-3649.0.	clinical manifestations	ileus	abdominal surgery	12	42	39	nasogastric tube/oral	7d	1.v
2005	2005-01-017	alone	neus	abdominar surgery	12	42	39	hasogastric tube/orar	74	1y
Gao ZJ	CNKI:SUN:SXZY.0.20	diagnostic imaging +	ileus	abdominal neoplasm or	15	60	51.75	nasogastric tube/oral	21d	N/A
2010	10-09-034	clinical manifestations	neus	peritonitis	13	00	51.75	nasogasure tube/ofai	210	1N/A
He GM	CNKI:SUN:ZDYS.0.20	diagnostic imaging +	mecha	abdominal surgery	50	97	40.6	nasogastric tube/oral	7d	N/A
2009	09-21-060	clinical manifestations	nical	abdominal surgery	50	50 97		hasogasule tube/olai	70	11/71
Hu ZG	CNKI:SUN:HNZG.0.20	diagnostic imaging +	mecha	N/A	59	126	52.5	(nasogastric	48h	1-5y

Yang et al., Afr J Tradit Complement Altern Med. (2014) 11(4):101-119 http://dx.doi.org/10.4314/ajtcam.v11i4.17

	up.//ux.u01.01g/10.431									
2008	08-04-030	clinical manifestations	nical					tube/oral) and rectal		
Jiang CL	CNKI:SUN:HNZY.0.20	diagnostic imaging +	mecha	abdominal surgery	58	110	34.6	rectal	N/A	N/A
2008	08-07-048	clinical manifestations	nical	abdominal surgery	50	110	54.0	Tectai	IN/A	1N/PA
Jiang K	CNKI:SUN:LZXB.0.20	diagnostic imaging +	ilaua	abdominal surgery	23	50	41.5	reatel	N/A	N/A
2009	09-04-071	clinical manifestations	ileus	abdominal surgery	23	50	41.5	rectal	IN/A	IN/A
I : II 2010	CNKI:SUN:GSZY.0.20	diagnostic imaging +	:1	- h. d	25	5.6	26.1		7.1	NT/A
Li H 2010	10-05-015	clinical manifestations	ileus	abdominal surgery	25	56	36.1	nasogastric tube/oral	7d	N/A
Li HS	cnki:ISSN:1004-745X.0.	clinical manifestations	mecha	NT/ A	50	212	20.0	<i>(</i> 1	401	< 70
2004	2004-08-022	alone	nical	N/A	50	212	30.9	rectal	48h	6-72m
Li HY	N/A	clinical manifestations	.,		1.60	1.60	20.5		27/1	N7/1
2006		alone	ileus	abdominal surgery	160	160	28.5	nasogastric tube/oral	N/A	N/A
	CNKI:ISSN:1006-978X.	diagnostic imaging +	mecha		24	54	41	. 1	151	27/4
Li R 2007	0.2007-01-010	clinical manifestations	nical	abdominal surgery	24	56	41	rectal	15d	N/A
Li ZY	cnki:ISSN:1000-7369.0.	clinical manifestations	.,		1.5	50	40 5		501	N7/1
2006	2006-01-038	alone	ileus	abdominal surgery	15	50	48.7	rectal	72h	N/A
Liang QF	cnki:ISSN:0256-7415.0.	diagnostic imaging +	mecha	11 . 1	20	51	26.0	. 1	21	NT/A
2004	2004-07-025	clinical manifestations	nical	abdominal surgery	29	51	36.9	rectal	3d	N/A
Liang	CNKI:SUN:YYXK.0.20	diagnostic imaging +	•1	11 . 1	25	C 0	41.05		7d	NT/ A
WH 2010	10-20-028	clinical manifestations	ileus	abdominal surgery	35	68	41.85	nasogastric tube/oral	/d	N/A
Liao DX	CNKI:SUN:SXLC.0.200	diagnostic imaging +	mecha	- h. d 1	52	136	N/A		N/A	1m
2009	9-28-022	clinical manifestations	nical	abdominal surgery	32	130	IN/A	nasogastric tube/oral	IN/A	1111
Liao ZY	cnki:ISSN:1008-2409.0.	clinical manifestations	ilaua	ab dominal supramy	20	80	37.5	no stal	99h	NI/A
2006	2006-04-043	alone	ileus	abdominal surgery	28	80	57.5	rectal	9911	N/A
Liu JS	N/A	clinical manifestations	mecha	ab dominal auroan	19	36	32.7	(nasogastric	N/A	N/A
1996		alone	nical	abdominal surgery	19	50	52.1	tube/oral) and rectal	IN/A	IN/A
Liu P	CNKI:SUN:ZGSQ.0.20	clinical manifestations	ilaua	ab dominal supromy	NI/A	207	NI/A	no otol	N/A	0.5.1.
2009	09-19-173	alone	ileus	abdominal surgery	N/A	207	N/A	rectal	IN/A	0.5-1y
Liu Q	NI/A	clinical manifestations	÷1	N/A	22	60	52 5	nonconstructure 1	N/A	NT / 4
2009	N/A	alone	ileus	IN/A	33	60	53.5	nasogastric tube/oral	IN/A	N/A
Liu XH	cnki:ISSN:1003-7705.0.	diagnostic imaging +	ilana	abdominal surrows	24	50	50.7	roctal	35d	114m
2005	2005-01-009	clinical manifestations	ileus	abdominal surgery	24	30	50.7	rectal	530	114m

Yang et al., Afr J Tradit Complement Altern Med. (2014) 11(4):101-119 http://dx.doi.org/10.4314/ajtcam.v11i4.17

	-									
Lu YH	CNKI:SUN:ZWYY.0.20	diagnostic imaging +	mecha	N/A	44	96	50	nasogastric tube/oral	7d	N/A
2008	08-07-050	clinical manifestations	nical	1 1/ 7 1		70	50	husogustrie tube/orur	74	10/11
Luo M	cnki:ISSN:1007-6948.0.	clinical manifestations	ileus	abdominal surgery	41	97	40.4	rectal	N/A	1-1.5y
2005	2005-01-011	alone	neus	abdommar surgery	71)1	-0	reetar	11/21	1-1.5y
Ma ZJ	cnki:ISSN:0256-7415.0.	clinical manifestations	ileus	fracture thoracic vertebrae or	20	60	N/A	nasogastric tube/oral	6d	N/A
2005	2005-07-015	alone	neus	lumbar vertebrae	20	00	N/A	hasogastric tube/orar	ou	IV/A
Peng T	CNKI:SUN:YXSS.0.201	diagnostic imaging +	mecha	abdominal surgery	35	116	42.4	nasogastric tube/oral	7d	N/A
2010	0-09-244	clinical manifestations	nical	abdommar surgery	55	110	42.4	hasogastric tube/orar	74	IV/A
Qiu JF	CNKI:SUN:XXYY.0.20	clinical manifestations	ileus	abdominal surgery	21	60	51.7	nasogastric tube/oral	N/A	N/A
2009	09-06-049	alone	neus	abdommar surgery	21	00	51.7	hasogastric tube/orai	IN/A	IN/A
Shen JQ	cnki:ISSN:1005-4561.0.	diagnostic imaging +	ileus	abdominal surgery,	20	56	34.8	(nasogastric	18d	N/A
2005	2005-10-005	clinical manifestations	neus	gastrointestinal neoplasm	20	50	54.0	tube/oral) and rectal	100	N/A
Su SH	CNKI:SUN:QKYX.0.20	diagnostic imaging +	ileus	N/A	6	15	N/A	nasogastric tube/oral	7d	N/A
2008	08-22-032	clinical manifestations	neus		0	15	N/A	hasogastric tube/orar	70	N/A
Sui J	CNKI:SUN:SYYZ.0.20	diagnostic imaging +	mecha	N/A	43	108	51.2	(nasogastric	7d	N/A
2010	10-12-078	clinical manifestations	nical	14/71	т.	100	51.2	tube/oral) and rectal	74	14/11
Sun JJ	cnki:ISSN:1000-7369.0.	clinical manifestations	ileus	abdominal surgery	155	302	67.8	nasogastric tube/oral	N/A	N/A
2006	2006-01-037	alone	neus	abdommar surgery	155	502	502 07.0	-	1011	11/71
Tang ZA	CNKI:SUN:SYLC.0.200	diagnostic imaging +	mecha	abdominal surgery	21	60	41.5	(nasogastric	10d	N/A
2008	8-11-065	clinical manifestations	nical	abdommar surgery	21	00	41.5	tube/oral) and rectal	100	11/21
Tao YJ	CNKI:SUN:XDJH.0.200	diagnostic imaging +	mecha	abdominal surgery	64	170	46.1	nasogastric tube/oral	4d	N/A
2008	8-21-058	clinical manifestations	nical	abdommar surgery	04	170	40.1	hasogastrie tube/orar	τu	14/14
Tong FG	N/A	clinical manifestations	mecha	N/A	22	64	N/A	nasogastric tube/oral	3d	N/A
2006		alone	nical	1 1/ / 1	22	01	10/11	husogustile tube/orui	54	14/11
Wang CG	CNKI:SUN:JYGZ.0.201	diagnostic imaging +	ileus	abdominal surgery	15	38	31.7	(nasogastric	10d	N/A
2010	0-02-032	clinical manifestations	neus		10	50	51.7	tube/oral) and rectal	104	1 1/ 2 1
Wang CH	CNKI:SUN:HNZY.0.20	clinical manifestations	ileus	abdominal surgery	150	150	44.8	nasogastric tube/oral	2d	N/A
2009	09-06-017	alone	neus	abdommar surgery	150	150	11.0	husogustile tube/ordi	24	11/21
Wang P	CNKI:ISSN:1004-0501.	diagnostic imaging +	mecha	tuberculous peritonitis	36	65	38.6	rectal	72h	N/A
2007	0.2007-05-042	clinical manifestations	nical	aberearous perionitis		55	20.0	reetur	, 211	1 1/ 2 1
Wang W	cnki:ISSN:1671-4040.0.	diagnostic imaging +	mecha	abdominal surgery	56	162	N/A	nasogastric tube/oral	N/A	N/A

Yang et al., Afr J Tradit Complement Altern Med. (2014) 11(4):101-119 http://dx.doi.org/10.4314/ajtcam.v11i4.17

	111p.//ux.u01.01g/10.451									
2004	2004-03-014	clinical manifestations	nical							
Wang YF	CNKI:SUN:PTGZ.0.200	diagnostic imaging +	mecha	- h-d	70	107	40		NT/A	NT/A
2009	9-05-009	clinical manifestations	nical	abdominal surgery	70	127	49	nasogastric tube/oral	N/A	N/A
Wen JY	CNKI:SUN:ZWYY.0.20	diagnostic imaging +	.1	11 . 1	12	22	40.0	<i>(</i> 1	NT/A	DT/A
2008	08-05-038	clinical manifestations	ileus	abdominal surgery	13	32	40.2	rectal	N/A	N/A
Wu CT	cnki:ISSN:1001-5426.0.	diagnostic imaging +	mecha	abdominal surgery	58	248	40.9	nasogastric tube/oral	24h	N/A
2003	2003-02-011	clinical manifestations	nical	abdominal surgery	38	248	40.9	hasogastric tube/orai	2411	IN/A
Wu DH	CNKI:SUN:FJZY.0.200	clinical manifestations	mecha	abdominal surgery	20	52	51.5	reatal	7d	N/A
2009	9-06-030	alone	nical	abdominal surgery	20	32	51.5	rectal	/u	IN/A
Xie ZC	CNKI:SUN:YLQY.0.20	diagnostic imaging +	mecha	abdominal surgery	59	125	37.5	rectal	N/A	N/A
2008	08-06-061	clinical manifestations	nical	abdominal surgery	39	125	57.5	Tectal	IN/A	IN/A
Xu HY	CNKI:SUN:MZMJ.0.20	diagnostic imaging +	ileus	abdominal surgery	25	80	63.9	nasogastric tube/oral	10d	N/A
2009	09-20-045	clinical manifestations	neus	abdominal surgery	23	00	05.7	hasogastric tube/orar	Tou	IV/A
Yang SZ	CNKI:SUN:JLYX.0.201	clinical manifestations	ileus	abdominal surgery	14	42	53.6	(nasogastric	N/A	N/A
2010	0-31-027	alone	neus	abdominal surgery	14	42	55.0	tube/oral) and rectal		IV/A
Ye B	N/A	diagnostic imaging +	mecha	abdominal surgery	43	70	N/A	(nasogastric	5d	N/A
2008		clinical manifestations	nical	abdommar surgery	-15	10	14/14	tube/oral) and rectal	54	14/24
You L	CNKI:SUN:SJZX.0.200	clinical manifestations	mecha	phytobezoar induced	35	96	37.3	nasogastric tube/oral	3d	N/A
2008	8-04-025	alone	nical	obstruction	55	70	57.5		50	11/11
Zhang Y	CNKI:ISSN:0256-7415.	diagnostic imaging +	mecha	abdominal surgery	41	97	38.8	(nasogastric	5d	N/A
2007	0.2007-01-006	clinical manifestations	nical	abdominar surgery	71	71	50.0	tube/oral) and rectal	54	14/14
Zhao Y	cnki:ISSN:0256-7415.0.	diagnostic imaging +	mecha	abdominal surgery	44	117	43.9	(nasogastric	3-5d	N/A
2006	2006-03-029	clinical manifestations	nical	abdominal surgery	++	117	+3.7	tube/oral) and rectal	3-3 u	IV/A
Zhao YL	N/A	clinical manifestations	ileus	abdominal surgery	82	162	46.1	nasogastric tube/oral	N/A	N/A
2006		alone	licus	abdommar surgery	02	102	40.1	hasogastrie tube/orar	14/11	
Zheng	CNKI:SUN:GDYY.0.20	diagnostic imaging +	mecha	abdominal surgery	40	100	46.5	(nasogastric	72h	N/A
HL 2010	10-04-071	clinical manifestations	nical	abdommar surgery	40	100	40.5	tube/oral) and rectal	/ 211	11/17
Zhou SY	CNKI:SUN:GYZX.0.20	diagnostic imaging +	mecha	abdominal surgery	40	86	44.5	(nasogastric	24h	N/A
2009	09-04-022	clinical manifestations	nical	abdominal surgery	40	00	74.5	tube/oral) and rectal	2711	$1\sqrt{A}$
Zhou YJ	cnki:ISSN:1004-745X.0.	diagnostic imaging +	mecha	abdominal surgery	16	78	45.8	(nasogastric	N/A	N/A
2001	2001-06-016	clinical manifestations	nical		10	10	+J.0	tube/oral) and rectal	11/71	11//A

http://dx.doi.org/10.4314/ajtcam.v11i4.17

Supplementary Table 2: Characteristics of the included RCTs (part B)

Trials	Interventions (experimental group)	Interventions (control group)	Outcomes
Ao XR 2007	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations
	antibiotics, laxatives (liquid paraffin), soapsuds enema, DCQD jiajian	fluid resuscitation, antibiotics, laxatives (liquid	
		paraffin), soapsuds enema	
Cao SB 2008	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations
	DCQD jiajian	fluid resuscitation	
Chen CQ	1) DCQD jiajian 2) cisapride 3*10mg/d, DCQD jiajian	cisapride 3*10mg/d	time to first stool, length of hospital stay
2002#			
Chen H 2009	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	time to first flatus, time to clinical/imaging manifestations
	DCQD <i>jiajian</i> 50mL/6h	fluid resuscitation antibiotics	improved, time to extubation, length of hospital stay
Chen ZJ 2004	bowel rest, decompression, antibiotics, intravenous fluid resuscitation,	bowel rest, decompression, antibiotics, intravenous fluid	time to first stool, improvement of clinical manifestations
	DCQD 200ml/12h	resuscitation	
Dong ZC 2008	bowel rest, decompression, intravenous fluid resuscitation, DCQD	bowel rest, decompression, intravenous fluid	improvement of clinical/imaging manifestations
	175ml/12h, antibiotics	resuscitation, soapsuds enema	
Dou WH 2009	bowel rest, decompression, antacid, intravenous fluid resuscitation,	bowel rest, decompression, antacid, intravenous fluid	improvement of clinical/imaging manifestations
	antibiotics, DCQD 200ml/24h	resuscitation, antibiotics	
Fan Y 2007	DCQD 200ml/24h	cisapride 3*5mg/d	time to first bowel movement, improvement of clinical
			manifestations
Fang HL 2008	bowel rest, decompression, intravenous fluid resuscitation, antibiotics,	bowel rest, decompression, intravenous fluid	time to first stool, improvement of clinical/imaging
	DCQD 200-300ml/24h	resuscitation, antibiotics	manifestations
Fu HB 2008	bowel rest, decompression, intravenous fluid resuscitation, antibiotics,	bowel rest, decompression, intravenous fluid	time to first stool, improvement of clinical/imaging
	DCQD 200ml/24h	resuscitation, antibiotics	manifestations
Gao JC 2005	decompression, intravenous fluid resuscitation, antibiotics, DCQD	decompression, intravenous fluid resuscitation,	time to first flatus, improvement of clinical manifestations
		antibiotics	
Gao ZJ 2010	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations, length of
	total parenteral nutrition, glucocorticoids, antibiotics, DCQD jiajian	fluid resuscitation, total parenteral nutrition,	hospital stay
	100ml/12h, metoclopramide 10mg	glucocorticoids, antibiotics	
He GM 2009	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations, length of
	total parenteral nutrition, glucocorticoids, antibiotics, DCQD jiajian	fluid resuscitation, total parenteral nutrition,	hospital stay

Yang et al., Afr J Tradit Complement Altern Med. (2014) 11(4):101-119 <u>http://dx.doi.org/10.4314/ajtcam.v11i4.17</u>

Hu ZG 2008	200ml/24h	glucocorticoids, antibiotics	
Hu ZG 2008	hand and interface and decomposition interface fluid according to the		
	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations
	total parenteral nutrition, coloclysis with physiological saline, DCQT	fluid resuscitation, total parenteral nutrition, coloclysis	
	jiajian	with physiological saline	
Jiang CL 2008	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations
	total parenteral nutrition, antibiotics, coloclysis with 200ml DCQT	fluid resuscitation, total parenteral nutrition, antibiotics,	
	jiajian(twice/day)	coloclysis with 200ml physiologic saline (twice/day)	
Jiang K 2009	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations
	somatostatin, histamine 2 blocking pharmacon, glucocorticoids, DCQD	fluid resuscitation, somatostatin, histamine 2 blocking	
	jiajian	pharmacon, glucocorticoids	
Li H 2010	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations, time to
	proton pump inhibitor, glucocorticoids, antibiotics, diuretic, DCQD	fluid resuscitation, proton pump inhibitor,	first flatus, time to first bowel movement, time to first
	jiajian	glucocorticoids, antibiotics, diuretic	stool, the duration of treatment
Li HS 2004	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	time to first stool, improvement of clinical manifestations
	antibiotics, DCQD jiajian 100ml(2 times/day),	fluid resuscitation, antibiotics	
Li HY 2006	DCQD jiajian	bowel rest, intubation and decompression, intravenous	time to first flatus
		fluid resuscitation	
Li R 2007	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations, length of
	somatostatin, histamine 2 blocking pharmacon, antibiotics, DCQD jiajian	fluid resuscitation, somatostatin, histamine 2 blocking	hospital stay
		pharmacon, antibiotics	
Li ZY 2006	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	time to first flatus, time to first stool, the gastrin level
	antibiotics, DCQD 200ml (twice/day)	fluid resuscitation, antibiotics	change, the vascular intestinal peptide(VIP) level
Liang QF 2004	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations
	antibiotics, DCQD jiajian 200ml (twice/day)	fluid resuscitation, antibiotics	
Liang WH	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	time to first flatus, time to first stool, time to
2010	antibiotics, glucocorticoids, somatostatin, DCQD jiajian	fluid resuscitation, antibiotics, glucocorticoids,	clinical/imaging manifestations improved, time to
		somatostatin	imaging improvement
Liao DX 2009	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations
	antibiotics, somatostatin, acupuncture moxibustion, DCQD jiajian,	fluid resuscitation, antibiotics, somatostatin, change	
	change position continuously	position continuously	
Liao ZY 2006	intubation and decompression, intravenous fluid resuscitation, antibiotics,	intubation and decompression, intravenous fluid	improvement of clinical manifestations, time to first

Yang et al., Afr J Tradit Complement Altern Med. (2014) 11(4):101-119 <u>http://dx.doi.org/10.4314/ajtcam.v11i4.17</u>

	DCOD	requestitation ontihistics calculation with alwared	flatus, time to first stand, time to alinical manifestations
	bcqb	resuscitation, antibiotics, coloclysis with glycerol	flatus, time to first stool, time to clinical manifestations
			improved
Liu JS 1996	intubation and decompression, intravenous fluid resuscitation, antibiotics,	intubation and decompression, intravenous fluid	time to first flatus, time to first stool, time to recovery of
	DCQD	resuscitation, antibiotics	body temperature, length of hospital stay, complications
Liu P 2009	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical manifestations
	antibiotics, vitamin B1, DCQD	fluid resuscitation, antibiotics, vitamin B1	
Liu Q 2009	antibiotics, DCQD	intubation and decompression, intravenous fluid	improvement of clinical manifestations
		resuscitation, antibiotics	
Liu XH 2005	bowel rest, intravenous fluid resuscitation, intubation and decompression,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations
	antibiotics, glucocorticoids, DCQD jiajian	fluid resuscitation, antibiotics, laxatives (glycerol, liquid	
		paraffin or castor oil)	
Lu YH 2008	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations
	antibiotics, DCQD	fluid resuscitation, antibiotics	
Luo M 2005	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	first bowel movement, time to first flatus, time to first
	antibiotics, DCQD	fluid resuscitation, antibiotics	stool
Ma ZJ 2005	intravenous fluid resuscitation, DCQD jiajian	intubation and decompression, laxative(glycerine enema	improvement of clinical manifestations
		or folium sennae), intravenous fluid resuscitation	
Peng T 2010	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	response rate, time to clinical/imaging manifestations
	antibiotics, somatostatin, DCQD jiajian	fluid resuscitation, antibiotics, somatostatin	improved
Qiu JF 2009	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	time to first stool
	antibiotics, DCQD jiajian 50ml/12h	fluid resuscitation, antibiotics, physiological saline	
		50ml/12h	
Shen JQ 2005	intubation and decompression, intravenous fluid resuscitation, antibiotics,	intubation and decompression, intravenous fluid	improvement of clinical/imaging manifestations, time to
	glucocorticoids, omatostatin, CQD jiajian 200ml/d	resuscitation, antibiotics, glucocorticoids, somatostatin	relief of symptome
Su SH 2008	DCQD jiajian(100ml/12h)	primperan 2*10mg/d and mosapride 3*5mg/d	improvement of clinical/imaging manifestations, time to
			bowel open
Sui J 2010	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations
	antibiotics, somatostatin, DCQD jiajian	fluid resuscitation, antibiotics, somatostatin	
Sun JJ 2006	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical manifestations, incidence of
	antibiotics, DCQD jiajian 100ml/12h	fluid resuscitation, antibiotics	complications
Tang ZA 2008	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical manifestations

Yang et al., Afr J Tradit Complement Altern Med. (2014) 11(4):101-119 <u>http://dx.doi.org/10.4314/ajtcam.v11i4.17</u>

nup./	/dx.dof.org/10.+514/ajtcam.v1114.17		
	antibiotics, DCQD jiajian	fluid resuscitation, antibiotics	
Tao YJ 2008	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations
	DCQD jiajian	fluid resuscitation	
Tong FG 2006	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical manifestations
	DCQD jiajian	fluid resuscitation, liquid paraffin	
Wang CG	analgesia, somatostatin, proton pump inhibitors, antibiotics,	analgesia, somatostatin, proton pump inhibitors,	improvement of clinical/imaging manifestations
2010	glucocorticoids (dexamethasone), DCQD jiajian	antibiotics, glucocorticoids (dexamethasone)	
Wang CH	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical manifestations
2009	antibiotics, somatostatin, proton pump inhibitors, DCQD jiajian	fluid resuscitation, antibiotics, somatostatin, proton	
	100ml/12h	pump inhibitors	
Wang P 2007	anti-tuberculosis, bowel rest, intubation and decompression, intravenous	anti-tuberculosis, bowel rest, intubation and	improvement of clinical/imaging manifestations
	fluid resuscitation, DCQD jiajian	decompression, intravenous fluid resuscitation	
Wang W 2004	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations
	antibiotics, DCQD jiajian	fluid resuscitation, antibiotics	
Wang YF 2009	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations, time to
	sandostatin, omeprazole, DCQD	fluid resuscitation, sandostatin, omeprazole	first flatus/stool, time to relief of abdominal pain, time to
			first bowel movement, time to improvement of imaging
			manifestations
Wen JY 2008	intubation and decompression, intravenous fluid resuscitation, antibiotics,	intubation and decompression, intravenous fluid	improvement of clinical/imaging manifestations
	DCQD jiajian	resuscitation, antibiotics	
Wu CT 2003	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	time to first stool, improvement of clinical/imaging
	antibiotics, DCQD	fluid resuscitation, antibiotics	manifestations
Wu DH 2009	intubation and decompression, intravenous fluid resuscitation, antibiotics,	intubation and decompression, intravenous fluid	improvement of clinical manifestations
	analgesia, DCQD	resuscitation, antibiotics, analgesia	
Xie ZC 2008	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations
	antibiotics, DCQD	fluid resuscitation, antibiotics	
Xu HY 2009	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	time to first flatus, time to first bowel movement, time to
	octreotide, ranitidine, dexamethasone, diuretics, antibiotics, DCQD jiajian	fluid resuscitation, octreotide, ranitidine,	relief of symptom, improvement of clinical/imaging
		dexamethasone, diuretics, antibiotics	manifestations
Yang SZ 2010	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	time to first flatus
	antibiotics, DCQD <i>jiajian</i>	fluid resuscitation, antibiotics	

Ye B 2008	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations
	antibiotics, DCQD jiajian	fluid resuscitation, antibiotics	
You L 2008	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	length of hospital stay, improvement of clinical
	soapsuds enema, antibiotics, DCQD jiajian, electro acupuncture	fluid resuscitation, soapsuds enema, antibiotics	manifestations
Zhang Y 2007	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations
	antibiotics, DCQD jiajian	fluid resuscitation, antibiotics	
Zhao Y 2006	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations
	antibiotics, CQD jiajian	fluid resuscitation, antibiotics	
Zhao YL 2006	DCQD jiajian	intubation and decompression, intravenous fluid	time to first flatus, time to first stool
		resuscitation, antibiotics	
Zheng HL	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations
2010	antibiotics, DCQD jiajian	fluid resuscitation, antibiotics	
Zhou SY 2009	bowel rest, intubation and decompression, laxatives (liquid paraffin),	bowel rest, intubation and decompression, laxatives	improvement of clinical/imaging manifestations
	intravenous fluid resuscitation, antibiotics, DCQD jiajian	(liquid paraffin), intravenous fluid resuscitation,	
		antibiotics	
Zhou YJ 2001	bowel rest, intubation and decompression, intravenous fluid resuscitation,	bowel rest, intubation and decompression, intravenous	improvement of clinical/imaging manifestations
	DCQD jiajian	fluid resuscitation	

http://dx.doi.org/10.4314/ajtcam.v11i4.17

Study or SubgroupEventsTotalEventsTotalWeightM-H. Random. 95% Cl1.1.1 lleus	Risk Ratio
Chen CQ 20022947384915.5%0.80 [0.61, 1.04]Liao ZY 20064040364027.6%1.11 [0.99, 1.24]Liu XH 20052425172514.9%1.41 [1.07, 1.87]Ma ZJ 20052930233019.8%1.26 [1.02, 1.55]Su SH 2008910251.7%2.25 [0.75, 6.71]Subtotal (95% Cl)15214979.5%1.14 [0.95, 1.39]Total events131116Heterogeneity: Tau ² = 0.03; Chi ² = 11.67, df = 4 (P = 0.02); l ² = 66%Test for overall effect: Z = 1.39 (P = 0.17)1.1.2 Mechanical Intestinal ObstructionFan Y 20072730253020.5%1.08 [0.88, 1.32]Subtotal (95% Cl)303020.5%1.08 [0.88, 1.32]Total events2725Heterogeneity: Not applicable2725451.08 [0.88, 1.32]Total events2725	M-H, Random, 95% Cl
Liao ZY 2006 40 40 36 40 27.6% 1.11 [0.99, 1.24] Liu XH 2005 24 25 17 25 14.9% 1.41 [1.07, 1.87] Ma ZJ 2005 29 30 23 30 19.8% 1.26 [1.02, 1.55] Su SH 2008 9 10 2 5 1.7% 2.25 [0.75, 6.71] Subtotal (95% Cl) 152 149 79.5% 1.14 [0.95, 1.39] Total events 131 116 Heterogeneity: Tau ² = 0.03; Chi ² = 11.67, df = 4 (P = 0.02); l ² = 66% Test for overall effect: Z = 1.39 (P = 0.17) 1.1.2 Mechanical Intestinal Obstruction Fan Y 2007 27 30 25 30 20.5% 1.08 [0.88, 1.32] Subtotal (95% Cl) 30 30 20.5% 1.08 [0.88, 1.32] Total events 27 25 Heterogeneity: Not applicable Test for overall effect: Z = 0.76 (P = 0.45)	
Liu XH 2005 24 25 17 25 14.9% 1.41 [1.07, 1.87] Ma ZJ 2005 29 30 23 30 19.8% 1.26 [1.02, 1.55] Su SH 2008 9 10 2 5 1.7% 2.25 [0.75, 6.71] Subtotal (95% Cl) 152 149 79.5% 1.14 [0.95, 1.39] Total events 131 116 Heterogeneity: Tau ² = 0.03; Chi ² = 11.67, df = 4 (P = 0.02); l ² = 66% Test for overall effect: Z = 1.39 (P = 0.17) 1.1.2 Mechanical Intestinal Obstruction Fan Y 2007 27 30 25 30 20.5% 1.08 [0.88, 1.32] Subtotal (95% Cl) 30 30 20.5% 1.08 [0.88, 1.32] Total events 27 25 Heterogeneity: Not applicable Test for overall effect: Z = 0.76 (P = 0.45)	
Ma ZJ 20052930233019.8%1.26 [1.02, 1.5]Su SH 2008910251.7%2.25 [0.75, 6.71]Subtotal (95% Cl)15214979.5%1.14 [0.95, 1.39]Total events131116Heterogeneity: Tau ² = 0.03; Chi ² = 11.67, df = 4 (P = 0.02); l ² = 66%Test for overall effect: Z = 1.39 (P = 0.17)1.1.2 Mechanical Intestinal ObstructionFan Y 20072730253020.5%1.08 [0.88, 1.32]Subtotal (95% Cl)303020.5%1.08 [0.88, 1.32]Total events2725Heterogeneity: Not applicable7525Heterogeneity: Not applicableTest for overall effect: Z = 0.76 (P = 0.45)5555	
Su SH 2008910251.7%2.25[0.75, 6.71]Subtotal (95% Cl)15214979.5%1.14[0.95, 1.39]Total events131116Heterogeneity: Tau ² = 0.03; Chi ² = 11.67, df = 4 (P = 0.02); l ² = 66%Test for overall effect: Z = 1.39 (P = 0.17)1.1.2 Mechanical Intestinal ObstructionFan Y 20072730253020.5%1.08 [0.88, 1.32]Subtotal (95% Cl)303020.5%1.08 [0.88, 1.32]Total events2725Heterogeneity: Not applicableTest for overall effect: Z = 0.76 (P = 0.45)	
Subtotal (95% Cl)15214979.5%1.14 [0.95, 1.39]Total events131116Heterogeneity: Tau² = 0.03; Chi² = 11.67, df = 4 (P = 0.02); l² = 66%Test for overall effect: Z = 1.39 (P = 0.17)1.1.2 Mechanical Intestinal ObstructionFan Y 20072730253020.5%1.08 [0.88, 1.32]Subtotal (95% Cl)303020.5%1.08 [0.88, 1.32]Total events2725Heterogeneity: Not applicableTest for overall effect: Z = 0.76 (P = 0.45)	
Total events131116Heterogeneity: Tau² = 0.03; Chi² = 11.67, df = 4 (P = 0.02); l² = 66%Test for overall effect: Z = 1.39 (P = 0.17) 1.1.2 Mechanical Intestinal Obstruction Fan Y 20072727302530205%1.08 [0.88, 1.32]Subtotal (95% Cl)30303020.5%1.08 [0.88, 1.32]Total events2725Heterogeneity: Not applicableTest for overall effect: Z = 0.76 (P = 0.45)	
Heterogeneity: Tau ² = 0.03; Chi ² = 11.67, df = 4 (P = 0.02); l ² = 66% Test for overall effect: Z = 1.39 (P = 0.17) 1.1.2 Mechanical Intestinal Obstruction Fan Y 2007 27 30 25 30 20.5% 1.08 [0.88, 1.32] Subtotal (95% Cl) 30 30 20.5% 1.08 [0.88, 1.32] Total events 27 25 Heterogeneity: Not applicable 25 30 Test for overall effect: Z = 0.76 (P = 0.45) 1.08 [0.45]	
Test for overall effect: $Z = 1.39$ (P = 0.17) 1.1.2 Mechanical Intestinal Obstruction Fan Y 2007 27 30 25 30 20.5% 1.08 [0.88, 1.32] Subtotal (95% CI) 30 30 20.5% 1.08 [0.88, 1.32] Total events 27 25 Heterogeneity: Not applicable 25 Test for overall effect: $Z = 0.76$ (P = 0.45)	
Test for overall effect: $Z = 1.39$ (P = 0.17) 1.1.2 Mechanical Intestinal Obstruction Fan Y 2007 27 30 25 30 20.5% 1.08 [0.88, 1.32] Subtotal (95% CI) 30 30 20.5% 1.08 [0.88, 1.32] Total events 27 25 Heterogeneity: Not applicable 25 Test for overall effect: $Z = 0.76$ (P = 0.45)	
Fan Y 2007 27 30 25 30 20.5% 1.08 [0.88, 1.32] Subtotal (95% CI) 30 30 20.5% 1.08 [0.88, 1.32] Total events 27 25 Heterogeneity: Not applicable 25 Test for overall effect: Z = 0.76 (P = 0.45)	
Subtotal (95% CI) 30 30 20.5% 1.08 [0.88, 1.32] Total events 27 25 Heterogeneity: Not applicable Test for overall effect: Z = 0.76 (P = 0.45)	
Total events2725Heterogeneity: Not applicableTest for overall effect: Z = 0.76 (P = 0.45)	
Heterogeneity: Not applicable Test for overall effect: $Z = 0.76$ (P = 0.45)	
Test for overall effect: $Z = 0.76$ (P = 0.45)	
Test for overall effect: $Z = 0.76$ (P = 0.45)	
Total (05% CI) 182 170 100 0% 1 13 [0 07 1 31]	
Total events 158 141	
Heterogeneity: Tau ² = 0.02; Chi ² = 11.81, df = 5 (P = 0.04); l ² = 58%	
Test for overall effect: $7 = 1.61 (P = 0.11)$ 0.5	0.7 1 1.5 2
Test for subgroup differences: Not applicable	vative Ther Favours DCQD

Figure 2: Effect of DCQD compared with conservative therapy in treatment of intestinal obstruction

DCQD, Da-Cheng-Qi decoction; 95% CI, 95% confidence interval

Note that Risk Ratio < 1 means numerically lower response rate than control group and RR > 1 numerically higher response rate than control group. 95% CI doesn't include the number 1 means statistical difference between the 2 groups.

http://dx.doi.org/10.4314/ajtcam.v11i4.17

	Exp	eriment	tal	C	Control			Std. Mean Difference	Std. Mean Difference	e
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV. Random, 95% 0	
1.1.1 DCQD vs CT										
Li HY 2006	20.5	7.5	80	64	7	80	49.8%	-5.97 [-6.70, -5.24]		
Liao ZY 2006	36.12	5.26	40	48.2	11.34	40	50.2%	-1.35 [-1.84, -0.87]	=	
Subtotal (95% CI)			120			120	100.0%	-3.65 [-8.17, 0.87]		
Heterogeneity: Tau ² =	10.55; C	chi² = 10)5.86, c	if = 1 (P	< 0.000	001); l²	= 99%			
Test for overall effect:	Z = 1.58	(P = 0.	11)							
1.1.2 DCQD+CT vs C	т									
Gao JC 2005	26.8	3.7	22	52.1	4.7	20	7.8%	-5.90 [-7.36, -4.45]		
Li H 2010	3.01	0.72	28	4.35	0.88	28	9.2%	-1.64 [-2.26, -1.03]		
Li ZY 2006	39.87	14.27	25	50.8	19.25	25	9.2%	-0.63 [-1.20, -0.07]		
Liang WH 2010	38.4	26.4	32	88.8	36	27	9.2%	-1.60 [-2.19, -1.00]		
Luo M 2005	32.66	15.35	53	83.56	25.6	44	9.2%	-2.45 [-2.98, -1.92]		
Qiu JF 2009	45.13	5.65	30	58.32	6.26	30	9.1%	-2.18 [-2.83, -1.54]		
Sun JJ 2006	70.6	7.1	151	121.2	17	151	9.4%	-3.87 [-4.26, -3.49]	-	
Wang CH 2009	43.38	20.3	45	40.1	20.52	45	9.3%	0.16 [-0.25, 0.57]	+	
Xu HY 2009	72.48	23.76	40	95.52	34.56	40	9.3%	-0.77 [-1.22, -0.31]	-	
Yang SZ 2010	163.2	100.8	22	254.4	88.8	20	9.1%	-0.94 [-1.58, -0.30]		
Zhao YL 2006	30.8	4.6	116	50.4	6.3	46	9.2%	-3.80 [-4.34, -3.26]	-	
Subtotal (95% CI)			564			476	100.0%	-2.09 [-3.04, -1.15]	•	
Heterogeneity: Tau ² =	2.46; Cł	ni² = 330).67, df	= 10 (P	< 0.000	001); l²	= 97%			
Test for overall effect:	Z = 4.33	(P < 0.	0001)							
								F		r
								-	10 -5 0	5 .

Figure 3: Forest plot of the time to first flatus

SMD, standardised mean difference; 95% CI, 95% confidence interval

Note that SMD < 0 means numerically time to first flatus in experiment group is shorter than control group and SMD > 0 numerically time to first flatus in experimental group is longer than control group. 95% CI doesn't include the number 0 means statistical difference between the 2 groups

Response to therapy in patients with mechanical intestinal obstruction

The 33 RCTs studying mechanical intestinal obstruction reported dichotomous data of 3,748 patients. Mechanical intestinal obstruction of 2,845 patients was caused by postoperative adhesion. Overall, 170 (8.4%) of 2,035 patients assigned to DCQD plus conservative therapy failed to respond to therapy compared with 498 (29.1%) of 1,713 patients allocated to conservative therapy (RR of respond =1.26; 95% CI 1.21 to 1.31 which favoured DCQD plus conservative therapy) (Fig 4), with no significant heterogeneity between studies (I^2 =38%) and an NNT of 5.3 (95% CI 4.5 to 5.9). There was no evidence of funnel plot asymmetry (Begg's test, p=0.05).

Given the borderline heterogeneity observed when results of individual RCTs were combined, we conducted pre-specified sensitivity analyses (Table 2). The RR of respond was relatively stable in all these analyses. Heterogeneity between trials was lower when only the 22 studies that administrate DCQD via oral or when only the 12 studies that via rectal were included in the analysis. In addition, the results of sensitivity analyses showed that DCQD administration via rectal seems to be more effective (NNT =4.2~95% CI 3.6 to 5.3). Treatment effect remained similar when only the 23 trials at moderate risk of bias were considered.

Discussion

This systematic review and meta-analysis has demonstrated that DCQD plus conservative therapy were more effective than conservative therapy alone for the treatment of intestinal obstruction, these beneficial effects appeared to exist for both ileus and mechanical intestinal obstruction. In addition, DCQD administration via rectal seems to be more effective. The RR of respond was relatively stable in all the sensitivity analyses. There was no statistical difference when we compared DCQD mono-therapy with conservative therapy alone. Although DCQD appear to be more effective than conservative therapy when the only two studies using clinical manifestations and imaging test improvement to define

http://dx.doi.org/10.4314/ajtcam.v11i4.17

response to treatment, considering there are only 60 subjects left in these two trials, we could draw no conclusion safely. For the continuous data of the time to first flatus, we found that DCQD plus conservative therapy could significantly shorten the duration of postoperative ileus in patients undergoing abdominal surgery.

Pharmacological studies and animal experiments have proved that effective components in DCQD could prevent intestinal adhesion by reducing the concentration of fibrinogen and raising that of fibrin degrading products in the intro-abdominal exudates after major abdominal surgery (Wang et al., 2004), and rhubarb in *Radix et Rhizoma Rhei* effects on colon (Jin et al, 2013) and increases the tension of it. Emodin can enhance the function of small intestinal peristalsis by mechanisms of promoting secretion of motilin, lowering the content of somatostatin and inhibiting sodium-potassium-exchanging ATPase activity of small intestinal mucosa (Zhang et al., 2005). Results of our research corroborated these previous pharmacological studies and animal experiments from another angle.

This systematic review has several strengths. To our knowledge, this is the first meta-analysis that focuses on the efficacy and safety of DCQD in the treatment of intestinal obstruction. The systematic review includes 60 RCTs with 6,095 patients, which makes it a powerful systematic review to analyze the efficacy and safety of DCQD. The study population well represented the general intestinal obstruction population in terms of age and pathogenesis. The success rate of conservative therapy alone was near to the previous study reported (Tanaka et al., 2008). We were also rigorous in describing our search strategy, eligibility criteria, and data extraction processes in detail. We conducted subgroup analysis to maintain clinical homogeneity in the patients, and sensitivity analyses according to risk of bias of included trials, route of administration, definition of response to therapy and aetiology to assess whether any of these trial characteristics affected overall efficacy. We used an intention-to-treat analysis, where all drop-outs assumed to be treatment failures, and pooled data with a random effects model, in order to reduce the likelihood that any beneficial effect of DCQD in intestinal obstruction has been overestimated.

Limitations of the present study, as with any systematic review and meta-analysis, arise from the quality and reporting of the RCTs included. Methodologies of RCTs conducted in mainland China where various and some of the included RCTs did not report their results according to the CONSORT checklist strictly. Blinding and allocation concealment were not reported in these RCTs, which means potential risk of bias. (Wood et al., 2008; He et al., 2011). There was borderline heterogeneity when dichotomous data were pooled, but our sensitivity analyses revealed plausible explanations for this. As for the significant heterogeneity when continuous data were pooled, the potential reasons may be the trials were carried out by surgeons with different technical levels, and clinical background was various among the subjects included, thus clinical heterogeneity inevitably existed. To perform subgroup analysis according to the type of surgical approach and the type of anaesthesia was meaningful, but we could not do this because little trials reported results separately by detailed clinical backgrounds. However, this problem did not prevent us from making a positive conclusion as other systematic reviews did. (Ford et al., 2009; Ford et al., 2011). Total adverse events data for DCQD via oral or rectal were sparse, this, however, may because the side-effects of short-term use of DCQD were light (Zhang et al., 2008;

Maxion-Bergemann et al., 2006; Kaszkin-Bettag et al., 2008) and easily be overwhelmed by the primary diseases. Lack of long-term follow-up prevented us from analysing the recurrence rate of intestinal obstruction. (Fevang et al., 2004) As limitations stated here, future well designed; randomised; double-blind; multicentre; long-term follow-up studies are needed to investigate these unanswered questions.

In summary, current guidelines for the management of intestinal obstruction from national and international do not pay much attention to any kinds of complementary and alternative medicine, (Diaz et al., 2008; Catena et al., 2011) evidence from this systematic review and meta-analysis supports the use of DCQD plus conservative therapy, which may increase the success rate of conservative therapy significantly and shorten the duration of postoperative ileus in patients undergoing abdominal surgery.

Contributors: Ling Tang acts as guarantor for the validity of the study report. Study concept and design: TL, LCQ. Acquisition of data: YB, XFY. Data Check: SHJ. Analysis and interpretation of data: YB, SHJ. Draft of manuscript: XFY, SXY. Critical revision of the manuscript for important intellectual content: ZZ, SXY. Statistical analysis: YB, XFY, SHJ.

Conflict of interest: All the authors declared no potential conflict of interest.

Primary Funding Source

This study was supported by the funds from the National Natural Science Foundation of China (81200111), Shanghai Health bureau (XYQ2011022), the Second Military Medical University (2011QN18) and Shanghai Municipal Science and Technology Commission (12ZR1439400).

Yang et al., Afr J Tradit Complement Altern Med. (2014) 11(4):101-119 http://dx.doi.org/10.4314/ajtcam.v11i4.17

	Verseever	19241	Pureate y ev				
22 0 02727010	DCQD		CT alo		10000000	Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Random, 95% C	M-H. Random, 95% Cl
1.1.1 lleus	20	122	(2205.0)	120	1222		
Cao SB 2008	31	35	21	34	1.3%	1.43 [1.07, 1.92]	
Chen CQ 2002	45	49	38	49	2.4%	1.18 [1.00, 1.41]	
Fu HB 2008	25	30	19	32	1.1%	1.40 [1.01, 1.95]	
Gao ZJ 2010	33	35 25	20 20	25 25	2.0%	1.18 [0.95, 1.46]	
Jiang K 2009	24		1100	1775	2.0%	1.20 [0.97, 1.48]	
Li H 2010 Liang WH 2010	27 32	28 34	22 27	28 34	2.0%	1.23 [1.00, 1.51] 1.19 [0.98, 1.43]	·
Liu P 2009	117	117	72	90	3.4%	1.25 [1.13, 1.39]	
Liu Q 2009	29	30	20	30	1.5%	1.45 [1.12, 1.88]	· · · · · · · · · · · · · · · · · · ·
Luo M 2005	40	43	29	39	2.1%	1.25 [1.02, 1.53]	
Shen JQ 2005	29	29	27	27	3.9%	1.00 [0.93, 1.07]	-
Wang CG 2010	20	20	15	18	1.9%	1.20 [0.96, 1.50]	
Wang CH 2009	50	75	42	75	1.6%	1.19 [0.92, 1.54]	
Wen JY 2008	15	16	11	16	1.0%	1.36 [0.96, 1.94]	
Xu HY 2009	38	40	29	40	2.1%	1.31 [1.07, 1.61]	
Subtotal (95% CI)	00	606	20	562	30.4%	1.23 [1.13, 1.34]	•
Total events	555		412			the former and	
Heterogeneity: Tau ² = 0		= 42 6		(P < 0	0001)- 12 =	= 67%	
Test for overall effect: 2				V			
1.1.2 Mechanical Inte	stinal Obs	structio	on				
Ao XR 2007	42	50	30	46	1.7%	1.29 [1.01, 1.64]	
Chen H 2009	34	37	23	28	2.1%	1.12 [0.92, 1.36]	
Chen ZJ 2004	24	30	12	20	0.8%	1.33 [0.89, 1.99]	
Dong ZC 2008	37	40	20	28	1.6%	1.29 [1.01, 1.66]	
Dou WH 2009	34	40	29	40	1.8%	1.17 [0.93, 1.48]	
Fang HL 2008	295	305	169	233	3.7%	1.33 [1.23, 1.45]	
He GM 2009	53	58	30	39	2.2%	1.19 [0.98, 1.44]	
Hu ZG 2008	63	69	41	57	2.4%	1.27 [1.06, 1.52]	
Jiang CL 2008	63	64	31	46	2.1%	1.46 [1.19, 1.79]	
Li HS 2004	106	112	60	93	2.6%	1.47 [1.25, 1.72]	
Li R 2007	27	28	23	28	2.2%	1.17 [0.97, 1.42]	20
Liang QF 2004	24	26	15	25	1.1%	1.54 [1.10, 2.16]	· · · · ·
Liao DX 2009	66	77	37	59	1.9%	1.37 [1.10, 1.70]	
Liu JS 1996	36	36	32	36	3.1%	1.12 [0.99, 1.27]	
Lu YH 2008	45	48	33	48	2.1%	1.36 [1.11, 1.67]	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Peng T 2010	36	38	34	39	2.8%	1.09 [0.94, 1.25]	
Sui J 2010	50	54	41	54	2.5%	1.22 [1.03, 1.44]	
Tang ZA 2008	28	30	21	30	1.6%	1.33 [1.04, 1.72]	
Tao YJ 2008	81	87	67	83	3.2%	1.15 [1.02, 1.30]	
Tong FG 2006	32	34	20	30	1.5%	1.41 [1.08, 1.84]	
Wang P 2007	31	37	16	28	1.0%	1.47 [1.03, 2.08]	
Wang W 2004	77	84	65	78	3.2%	1.10 [0.98, 1.24]	
Wang YF 2009	62	65	53	62	3.2%	1.12 [0.99, 1.25]	
Wu CT 2003	119	140	64	108	2.4%	1.43 [1.21, 1.70]	
Wu DH 2009	25	26	19	26	1.7%	1.32 [1.03, 1.68]	
Xie ZC 2008	61	63	46	62	2.7%	1.31 [1.12, 1.52]	
Ye B 2008	38	40	24	30	2.2%	1.19 [0.98, 1.44]	
You L 2008	31	48	12	48	0.5%	2.58 [1.52, 4.40]	
Zhang Y 2007	51	54	35	43	2.6%	1.16 [0.99, 1.36]	
Zhao Y 2006	59	65	37	52	2.2%	1.28 [1.06, 1.54]	
Zheng HL 2010	55	60	28	40	1.9%	1.31 [1.05, 1.63]	
Zhou SY 2009	38	44	29	42	1.8%	1.25 [0.99, 1.58]	
Zhou YJ 2001	42	46	19	32	1.3%	1.54 [1.14, 2.08]	
Subtotal (95% CI)		2035	40.10	1713	69.6%	1.26 [1.21, 1.31]	
Total events	1865		1215	-			
Heterogeneity: Tau ² = 0 Test for overall effect: 2				(P = 0	02); l² = 3	8%	
Total (95% CI)		2641		2275	100.0%	1.25 [1.20, 1.30]	•
Total events	2420		1627				
Heterogeneity: Tau ² = (0.01; Chi ²	= 104.4	46, df = 4	7 (P <	0.00001);	l² = 55%	
Test for overall effect: 2				88	91		0.5 0.7 1 1.5 2 Favours CT alone Favours DCQD+CT
Test for subaroup diffe	rences: No	ot apoli	cable				ravous or alone ravours DOQD+C1

Figure 4: Effect of DCQD plus conservative therapy compared with conservative therapy in treatment of intestinal obstruction

CT, conservative therapy; DCQD, Da-Cheng-Qi decoction; 95% CI, 95% confidence interval

Note that RR < 1 means numerically lower response rate than control group and RR > 1 numerically higher response rate than control group. 95% CI doesn't include the number 1 means statistical difference between the 2 groups.

References

- 1. Begg CB, Mazumdar M. (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics. Dec;50(4):1088-101.
- Catena F, Di Saverio S, Kelly MD, Biffl WL, Ansaloni L, Mandalà V, Velmahos GC, Sartelli M, Tugnoli G, Lupo M, Mandalà S, Pinna AD, Sugarbaker PH, Van Goor H, Moore EE, Jeekel J. (2011). Bologna Guidelines for Diagnosis and Management of Adhesive Small Bowel Obstruction (ASBO): 2010 Evidence-Based Guidelines of the World Society of Emergency Surgery. World J Emerg Surg. Jan 21;6:5.
- 3. DerSimonian R, Laird N. (1986). Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
- Diaz JJ Jr, Bokhari F, Mowery NT, Acosta JA, Block EF, Bromberg WJ, Collier BR, Cullinane DC, Dwyer KM, Griffen MM, Mayberry JC, Jerome R. (2008). Guidelines for management of small bowel obstruction. J Trauma. Jun;64(6):1651-64.
- 5. Fevang BT, Jensen D, Svanes K, Viste A. (2002). Early operation or conservative management of patients with small bowel obstruction? Eur J

http://dx.doi.org/10.4314/ajtcam.v11i4.17

Surg.168(8-9):475-81.

- Fevang BT, Fevang J, Lie SA, Søreide O, Svanes K, Viste A. (2004). Long-term prognosis after operation for adhesive small bowel obstruction. Ann Surg. Aug;240(2):193-201.
- Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. (2009). Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. Mar;58(3):367-78.
- Ford AC, Suares NC. (2011). Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut. Feb;60(2):209-18.
- Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C; CONSORT Group. (2006). Recommendations for reporting randomized controlled trials of herbal interventions: Explanation and elaboration. J Clin Epidemiol. Nov;59(11):1134-49.
- 10. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C; CONSORT Group. (2006). Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med. Mar 7;144(5):364-7.
- Gong H, Tang W, Wang H, Xia Q, Huang X. (2011). Effects of food and gender on the pharmacokinetics of rhein and emodin in rats after oral dosing with Da-Cheng-Qi decoction. Phytother Res. Jan;25(1):74-80.
- 12. He J, Du L, Liu G, Fu J, He X, Yu J, Shang L. (2011). Quality assessment of reporting of randomization, allocation concealment, and blinding in traditional Chinese medicine RCTs: a review of 3159 RCTs identified from 260 systematic reviews. Trials. May 13;12:122.
- Jin R, Lin ZJ, Xue CM, Zhang B. (2013). An improved association-mining research for exploring Chinese herbal property theory: based on data of the Shennong's Classic of Materia Medica. J Integr Med. Sep;11(5):352-65.
- 14. Kaszkin-Bettag M, Richardson A, Rettenberger R, Heger PW. (2008). Long-term toxicity studies in dogs support the safety of the special extract ERr 731 from the roots of Rheum rhaponticum. Food Chem Toxicol. May;46(5):1608-18.
- 15. Kumar S, Wong PF, Leaper DJ. (2009). Intra-peritoneal prophylactic agents for preventing adhesions and adhesive intestinal obstruction after non-gynaecological abdominal surgery. Cochrane Database Syst Rev. Jan 21;(1):CD005080.
- Markogiannakis H, Messaris E, Dardamanis D, Pararas N, Tzertzemelis D, Giannopoulos P, Larentzakis A, Lagoudianakis E, Manouras A, Bramis I. (2007). Acute mechanical bowel obstruction: clinical presentation, etiology, management and outcome. World J Gastroenterol. Jan 21;13(3):432-7.
- 17. Maxion-Bergemann S, Bornhöft G, Sonderegger E, Renfer A, Matthiessen PF, Wolf U. (2006). Traditional Chinese medicine (phytotherapy): Health Technology Assessment report selected aspects. Forsch Komplementmed. 13 Suppl 2:30-41.
- 18. Moran BJ. (2007). Adhesion-related small bowel obstruction. Colorectal Dis. Oct;9 Suppl 2:39-44.
- 19. Qi QH, Wang J, Hui JF. (2004). Effect of dachengqi granule on human gastrointestinal motility. Zhongguo Zhong Xi Yi Jie He Za Zhi. Jan;24(1):21-4.
- Qi QH, Wang J, Liang GG, Wu XZ. (2007). Da-Cheng-Qi-Tang promotes the recovery of gastrointestinal motility after abdominal surgery in humans. Dig Dis Sci. Jun;52(6):1562-70.
- 21. Satoh H. (2013). Pharmacological characteristics of Kampo medicine as a mixture of constituents and ingredients. J Integr Med. Jan;11(1):11-6.
- 22. Tanaka S, Yamamoto T, Kubota D, Matsuyama M, Uenishi T, Kubo S, Ono K. (2008). Predictive factors for surgical indication in adhesive small bowel obstruction. Am J Surg. Jul;196(1):23-7.
- Tang WF, Wan MH, Huang QR, Zhu ZY, Zhao JL, Wu YZ, Huang X. (2008). Effect of Da-Cheng-Qi decoction on the pharmacokinetics of ranitidine in rats. Biomed Chromatogr. Aug;22(8):851-6.
- Wang YL, Pan CE, Yang PL, Tian Y, Pei SW, Dong M. (2004). Effects of Antiadhesion preparation on free fibrinogen and fibrin degrading products in abdominal exudates of rabbits postoperatively. World J Gastroenterol. Sep 15;10(18):2762-6.
- Williams SB, Greenspon J, Young HA, Orkin BA. (2005). Small bowel obstruction: conservative vs. surgical management.. Dis Colon Rectum. Jun;48(6):1140-6.
- Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne JA. (2008) Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. Mar 15;336(7644):601-5.
- 27. Xu F, Liu Y, Dong H, Song R, Zhang Z. (2010). Pharmacokinetic comparison in rats of six bioactive compounds between Da-Cheng-Qi decoction and its parent herbal medicines. Nat Prod Commun. May;5(5):795-800.
- Zhang HQ, Zhou CH, Wu YQ. (2005). Effect of emodin on small intestinal peristalsis of mice and relevant mechanism. World J Gastroenterol. May 28;11(20):3147-50.
- Zhang MJ, Zhang GL, Yuan WB, Ni J, Huang LF. (2008). Treatment of abdominal compartment syndrome in severe acute pancreatitis patients with traditional Chinese medicine. World J Gastroenterol. Jun 14;14(22):3574-8.